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Truncating Mutations of MAGEL2,
a Gene within the Prader-Willi Locus,
Are Responsible for Severe Arthrogryposis
Dan Mejlachowicz,1 Flora Nolent,1 Je´rome Maluenda,1 Hanitra Ranjatoelina-Randrianaivo,2
Fabienne Giuliano,3 Ivo Gut,4 Damien Sternberg,5 Annie Laquerrie`re,6 and Judith Melki1,*
Arthrogryposis multiplex congenita (AMC) is characterized by the presence of multiple joint contractures resulting from reduced or ab-
sent fetal movement. Here, we report two unrelated families affected by lethal AMC. By genetic mapping and whole-exome sequencing
in a multiplex family, a heterozygous truncating MAGEL2 mutation leading to frameshift and a premature stop codon (c.1996delC,
p.Gln666Serfs*36) and inherited from the father was identified in the probands. In another family, a distinct heterozygous truncating
mutation leading to frameshift (c.2118delT, p.Leu708Trpfs*7) and occurring de novo on the paternal allele ofMAGEL2was identified in
the affected individual. In both families, RNA analysis identified the mutated paternalMAGEL2 transcripts only in affected individuals.
MAGEL2 is one of the paternally expressed genes within the Prader-Willi syndrome (PWS) locus. PWS is associated with, to varying ex-
tents, reduced fetal mobility, severe infantile hypotonia, childhood-onset obesity, hypogonadism, and intellectual disability. MAGEL2
mutations have been recently reported in affected individuals with features resembling PWS and called Schaaf-Yang syndrome. Here,
we show that paternalMAGEL2mutations are also responsible for lethal AMC, recapitulating the clinical spectrum of PWS and suggest-
ing that MAGEL2 is a PWS-determining gene.Arthrogryposis multiplex congenita (AMC) has an overall
incidence of one in 3,000 live births.1,2 Some non-genetic
factors, such as mechanical limitation of fetal movements
or maternal autoimmune myasthenia, might cause AMC.
Isolated AMC is the direct consequence of fetal akinesia
and/or hypokinesia sequence. Isolated AMC is genetically
heterogeneous and caused bymutations of genes encoding
components required for the formation or the function of
the neuromuscular junction, including CHRNG (MIM:
100730), CHRNA1 (MIM: 100690), CHRND (MIM:
100720), CHRNB1 (MIM: 100710), DOK7 (MIM: 610285),
RAPSN (MIM: 601592), and CHAT (MIM: 118490); or the
skeletal muscle, including TPM2 (MIM: 190990), MYH2
(MIM: 160740), MYH3 (MIM: 160720), MYH8 (MIM:
160741), TNNI2 (MIM: 191043), TNNT3 (MIM: 600692),
MYBPC1 (MIM: 160794), DMPK (MIM: 605377), ACTA1
(MIM: 102610), NEB (MIM: 161650), RYR1 (MIM:
180901), SYNE1 (MIM: 608441), PIEZO2 (MIM: 613629),
and TTN (MIM: 188840); or the survival of motor neu-
rons or myelination of peripheral nerves, including GLE1
(MIM: 603371), PIP5K1C (MIM: 606102), ERBB3 (MIM:
190151), SMN1 (MIM: 600354), TRPV4 (MIM: 605427),
ADCY6 (MIM: 600294), CNTNAP1 (MIM: 602346),
ECEL1 (MIM: 605896), and GPR126 (MIM: 612243). The
difficulty in establishing a genetic diagnosis for AMC-
affected individuals is due to high genetic heterogeneity
and/or to the existence of some not-yet-identified dis-
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informed consent for genetic analysis of their children or
fetuses and themselves in accordance with the ethical
standards of our institutional review boards. In family 1,
three affected fetuses were born to non-consanguineous
healthy parents (Figure 1). According to ultrasound exam-
ination, the first fetus displayed reduced mobility detect-
able from 22 weeks of gestation (w.g.) and associated
with polyhydramnios and unilateral club foot. Karyotype
analysis was 46, XX. Fetal death was observed at 24 w.g.
Fetopathological examination revealed severe microre-
trognathia associated with short palpebral fissures, hyper-
telorism, a short and large neck, bilateral club foot, flexion
of elbows and knees, and camptodactyly of the fingers
(Figure S1). For the second fetus, ultrasound examination
revealed bilateral club foot associated with polyhydram-
nios and bilateral camptodactyly at 23 w.g. Fetal death
was observed at 24 w.g. Pathological examination revealed
an identical phenotype in this male fetus. Morphological
examination of the brain, spinal cord, and the neuromus-
cular system did not reveal any specific defect. The third
fetus, a male, was also affected with an identical pheno-
type and died at 27 w.g. Genetic mapping of disease loci
was performed in the family with Affymetrix GeneChip
Human Mapping 250K microarrays. Multipoint linkage
analysis of SNP data was performed with the Alohomora3
and Merlin softwares.4 Whole-exome sequencing (WES)
of the first fetus was performed with the Exome Capture76, France; 2Medical Genetic Unit, South University Hospital, St Pierre-La
Malformations, University Hospital of Nice, Nice, 06000, France; 4Centro
chimie Me´tabolique and UMR 1127-7225, Hoˆpitaux Universitaires Pitie´-
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Figure 1. Truncating Mutation of
Paternal MAGEL2 Allele in Family 1 and
RNA Studies
(a) Sequencing of DNA showing the
MAGEL2 c.1996delC mutation in family 1
(I:2; II:2; III-1 to III-3). Arrows indicate
mutant nucleotide position.
(b) PCR analysis of MAGEL2 (1–4, 660 bp)
and b-actin (5 and 6, 250 bp) in affected
individuals (2, 4, and 6) and control indi-
viduals (1, 3, and 5) after reverse transcrip-
tion (RT; 1 and 2) or without RT of RNA
(3 and 4). Note the marked reduction of
MAGEL2 in the affected individual (2)
with respect to the control individual (1)
and b-actin (5 and 6). MW, molecular
weight.
(c) Sequencing of the MAGEL2 RT-PCR
products showing the paternally mutated
allele only in the affected individual.Agilent SureSelect XT V5 Kit for library preparation and
exome enrichment as previously described.5 Sequencing
was performed on a Genome Analyzer IIx Illumina instru-
ment with paired-end 75 bp reads. The median coverage of
the WES was 72. Reads were aligned to the human refer-
ence genome sequence (NCBI Genome browser build
37.3) via the Burrows-Wheeler Aligner program.6 Variants
were selected with the SAMtools7 then annotated with
ANNOVAR.8 Variants in coding regions (including non-
synonymous and nonsense mutations), intron-exon
junctions, or short coding insertions or deletions were
selected when the minor allele frequency was less than
0.003. Variants mapping to the candidate regions, as
determined by linkage analysis, were selected. Under
the hypothesis of autosomal-recessive inheritance, no
candidate variants were identified. Under the hypothe-
sis of paternally autosomal-dominant inheritance, a
heterozygous 1 bp deletion in MAGEL2 (c.1996delC
[GenBank:NM_019066.4]), leading to frameshift and a
premature stop codon (p.Gln666Serfs*36; Figure 1), was
identified within the 15q11.2 region, one of the linked dis-
ease loci (Figure 1). Sanger sequencing of PCR products via
primers flanking the mutation (Table S1) confirmed the
mutation in the three affected fetuses (III:1 to III:3;
Figure 1) and showed that it was inherited from the unaf-
fected father (II:2; Figure 1). Analysis of the father’s parents
indicated that the mutation was inherited from the unaf-
fected grandmother (I:2; Figure 1). Via both WES and
microarray data, a total of 240 SNPs were identified in
this family at the Prader-Willi locus at an average distance
of 6.4 Kb. In 140 of them, heterozygosity was observed in
the affected fetuses. At the SNORD116 snoRNA cluster,
79 out of 87 SNPs were found to be heterozygous (data
not shown, available on request). These data exclude a
large heterozygous deletion or maternal uniparental dis-
omy at this locus. Given that MAGEL2 is only expressed
from the paternal allele, MAGEL2 RNA analysis was per-
formed from skeletal muscle of an affected fetus. Because
MAGEL2 is a single-exon gene, and to avoid contamina-
tion of RNA by DNA, RNA was treated with DNaseThe AmericRNase-Free (Macherey-Nagel). Then, MAGEL2 PCR anal-
ysis was performed from RNA before or after reverse tran-
scription (SuperScript III Reverse Transcriptase, Invitrogen,
Table S1). In comparison to b-actin expression in control
RNA, a marked reduction of MAGEL2 expression was
observed in affected individuals (Figure 1). Importantly,
sequence analysis of RT-PCR product revealed the pater-
nally mutated allele, only indicating the absence of mater-
nally expressed MAGEL2 allele in the affected individuals
(Figure 1 and Table S1).
Sanger sequencing of MAGEL2 in additional affected in-
dividuals or fetuses with arthrogryposis and/or reduced
fetal mobility (n ¼ 84) of unknown origin allowed the
identification of a distinct truncatingmutation ofMAGEL2
in another affected individual (II:1, family 2; Figure 2).
In this family, the female affected individual was born
to non-consanguineous healthy parents. The abnormal
phenotype was discovered at birth and was characterized
by microretrognathia, a short neck, bilateral camptodac-
tyly of the third and fourth fingers, and bilateral club
foot. The newborn displayed severe hypotonia with respi-
ratory distress from birth and died at postnatal day 2. Path-
ological examination of the brain, spinal cord, and other
organs was normal. Array comparative genomic hybridiza-
tion was normal, as well as Sanger sequencing of CHRNG,
CHRNA1, CHRNB1, CHRND, RAPSN, DOK7, and CHAT.
The DMPK locus was normal. Paternal deletion of 15q11–
15q13 andmaternal uniparental disomy 15 were excluded.
Through sequencing ofMAGEL2, a heterozygous 1 bp dele-
tion in MAGEL2 (c.2118delT [GenBank: NM_019066.4]),
leading to frameshift and a stop codon (p.Leu708Trpfs*7;
Figure 2 and Table S1), was identified in this affected indi-
vidual (II:1). Analysis of both parents showed that the
mutation had occurred de novo. To determine whether
the de novo MAGEL2 mutation occurred on the paternal
or maternal allele, MAGEL2 RNA analysis was performed
from affected-individual fibroblasts. Sequence analysis
of RT-PCR was performed via primers flanking the frame-
shift deletion as well as a SNP (rs2233070) located in
MAGEL2 and inherited from the mother (I:2; Figure 2an Journal of Human Genetics 97, 616–620, October 1, 2015 617
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Figure 2. De Novo Truncating Mutation Occurring on the
Paternal MAGEL2 Allele in Family 2 and RNA Studies
(a) Sequencing of DNA showing the de novoMAGEL2 c.2118delT
mutation in affected individual II:1. Arrows indicate mutant
nucleotide position. Sequencing of MAGEL2 RT-PCR products
(RNA) from affected individual II:1 revealed the mutated allele
only.
(b) Sequencing of DNA showing the rs2233070 polymorphism in-
herited from the mother (I:2 and II:1, arrow). Sequencing of
MAGEL2 RT-PCR products (RNA) from affected individual II:1
revealed the paternal allele only.and Table S1). Importantly, sequence analysis of RT-PCR
product revealed the frameshift deletion allele only and
the lack of the maternal SNP allele, indicating that the
deleterious de novo MAGEL2 mutation occurred on the
paternal allele (II:1; Figure 2). Marked reduction of
MAGEL2 expression was observed in the affected individ-
ual (data not shown). These two truncating mutations
were found neither in the current Exome Variant Server
database (ESP6500SI-V2) nor in the Single Nucleotide Poly-
morphism Database (dbSNP v.144).
MAGEL2 is one of the paternally expressed genes
located within the Prader-Willi syndrome (PWS) locus.
PWS is associated with, to varying extents, reduced
fetal mobility, distal joint contractures, neonatal hypo-
tonia with respiratory distress, early-childhood-onset
obesity, intellectual disability, hypogonadotropic hypogo-
nadism, and short stature. PWS can result from paternal
deletion of 15q11–15q13 (in 65%–75% of affected indi-
viduals), maternal uniparental disomy 15 (in 20%–30%
of affected individuals), or, more rarely, an imprinting
defect or microdeletion including the SNORD116
cluster (reviewed in Cassidy et al.9). The Prader-Willi locus
contains five paternally expressed genes (MKRN3,
MAGEL2, NDN, NPAP1, and SNURF-SNRPN) and a family
of six paternally expressed snoRNA genes or clusters.9
PWS has been suggested as being a contiguous gene
syndrome.
PWS has been reported in fetuses with polyhydramnios
associated with reduced fetal mobility and distal arthrogry-
posis.10–13 In these cases, paternal 15q11–15q13 deletion
or maternal uniparental disomy of 15q11.2–15q12 were
identified, and it was suggested that PWS should be consid-
ered in fetuses with polyhydramnios and/or abnormal fetal618 The American Journal of Human Genetics 97, 616–620, Octoberposition, especially if diminished fetal movements are re-
ported. Here, we report four affected individuals from
two unrelated families who have a phenotype very similar
to those previously reported10–13 and who carry heterozy-
gous truncating mutations on the paternal allele of
MAGEL2. These mutations are either inherited from or
occurred de novo on the paternal allele, indicating that
truncating mutations in MAGEL2 are responsible for this
condition. Appropriate genetic information from other
members of the family might need to be provided, espe-
cially when a paternally mutated allele identified
in affected individuals is transmitted silently from the
grandmother.
Recently, truncating mutations of MAGEL2 have been
identified on the paternal allele of four affected individuals
with features resembling PWS and called Schaaf-Yang syn-
drome (MIM: 615547).14,15 However, another affected in-
dividual carrying a large paternally inherited deletion of
3.9 Mb that includes MAGEL2, but not the SNRPN-
SNORD116 locus, was reported as not showing intellectual
disability at 3 years of age, but did show transient neonatal
hypotonia associated with a slight delay of fine motor
skills.16
These data revealed that intragenic mutations or dele-
tion of the paternal allele of MAGEL2 result in a large
clinical spectrum, ranging from a severe fetal phenotype
characterized by polyhydramnios, reduced fetal mobility
and distal joint contractures (our report), and syn-
dromic intellectual disability or autism (Schaaf-Yang syn-
drome)14,15 to an abnormal position of distal joints with
a slight delay of fine motor skills without intellectual
disability.16 Of note, three out of four affected individuals
reported by Schaaf et al.14 displayed neonatal hypotonia
and feeding problems with the need for special feeding
techniques, and in two out of four affected individuals,
contractures of the proximal and distal interphalangeal
joints were reported. These data strongly support the
view that MAGEL2 intragenic mutations recapitulate the
PWS phenotype.
Recently, Matarazzo and Muscatelli (2013)17 detected
Magel2 transcripts in the brains of mice deleted for the
paternal allele of Magel2, indicating an incomplete
silencing of the maternal allele. Interestingly, paternally
Magel2-null mice have reduced embryonic viability (in
10% to 30% of embryos) but otherwise normal embryonic
growth in survivors, followed by post-natal growth retarda-
tion and excessive weight gain, recapitulating aspects of
the PWS phenotype.18,19 Similarly, Guo et al.20 have re-
ported an imprinting variance of Magel2 in pigs during
fetal development. These data suggest that the imprinting
pattern of MAGEL2, as well as other genes at the PWS
locus, could be regulated during development by trans
effects on the maternal allele. We hypothesize that the
clinical expression of PWS might depend on the temporal
or spatial variation in expression of the maternal MAGEL2
allele and that a complete lack of maternal MAGEL2 allele
expression is responsible for early-onset and very severe1, 2015
disease phenotypes. However, we cannot exclude a role of
other genes linked or not to the PWS locus in the clinical
expression of PWS.
During mouse embryogenesis, Magel2 expression is
restricted to the neural tube, forebrain, midbrain, and
hypothalamus, as well as to the dorsal root ganglia and
peripheral neurons innervating limb and trunk mus-
cles.19 In non-neuronal tissues, Magel2 expression is
confined to the genital tubercle, midgut region, and
placenta. In affected individuals with PWS, neuromus-
cular studies including muscle biopsy are generally
normal or show non-specific signs suggesting that the
motor deficit is of central origin. The expression
pattern of MAGEL2 in the CNS during development and
the fetal onset of motor defects associated with truncating
mutations of MAGEL2 reported here strongly suggest that
MAGEL2 has an essential role in neuronal development.
The expression pattern of maternal MAGEL2 warrants
further investigation in the nervous system during
development.
Altogether, these data strongly suggest that MAGEL2 is
a PWS-determining gene. In the absence of paternal
deletion of 15q11–15q13 or maternal uniparental disomy
15, a search for intragenic mutations on the paternal
allele of MAGEL2 should be proposed for fetuses
with reduced movements, polyhydramnios, and distal
arthrogryposis, newborns with severe undiagnosed cen-
tral hypotonia, or children for whom PWS is clinically
suspected.Supplemental Data
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